Jimmy J Hwang

Summary

Affiliation: Georgetown University
Country: USA

Publications

  1. ncbi request reprint Role of chemotherapy in the treatment of gastroesophageal cancers
    Jimmy J Hwang
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Oncology (Williston Park) 21:579-86; discussion 587, 591-2. 2007
  2. pmc A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors
    John Marshall
    Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA
    Invest New Drugs 31:399-408. 2013
  3. ncbi request reprint Combined inhibition of topoisomerases: a phase I. Study of irinotecan and epirubicin
    Jimmy J Hwang
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, USA
    Oncology (Williston Park) 17:46-51. 2003
  4. ncbi request reprint Improving the toxicity of irinotecan/5-FU/leucovorin: a 21-day schedule
    Jimmy J Hwang
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, USA
    Oncology (Williston Park) 17:37-43. 2003
  5. ncbi request reprint Irinotecan and 5-FU/ leucovorin in metastatic colorectal cancer: balancing efficacy, toxicity, and logistics
    Jimmy J Hwang
    Lombardi Comprehensive Cancer Center Washington, DC 20007, USA
    Oncology (Williston Park) 18:26-34. 2004
  6. ncbi request reprint Locally advanced esophageal carcinoma: at the crossroads of evidence-based medicine and patient care
    Jimmy J Hwang
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Clin Adv Hematol Oncol 1:289-91; discussion 292. 2003
  7. ncbi request reprint Capecitabine: fulfilling the promise of oral chemotherapy
    Jimmy J Hwang
    Georgetown University Medical Center, Lombardi Cancer Center, Washington DC 20007, USA
    Expert Opin Pharmacother 3:733-43. 2002
  8. pmc A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies
    Michael J Pishvaian
    Lombardi Comprehensive Cancer Center, Developmental Therapeutics Program, Georgetown University Medical Center, Washington, DC 20007, USA
    Cancer 118:5403-13. 2012
  9. pmc Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic cancer
    Xuefei Tian
    Division of Hematology and Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA
    Oncol Lett 11:1645-1650. 2016
  10. pmc Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma
    Jimmy J Hwang
    Lombardi Cancer Center, Georgetown Medical Center, 3800 Reservoir Road NW, Washington, DC 20007 2113, USA
    Clin Cancer Res 16:4038-45. 2010

Detail Information

Publications13

  1. ncbi request reprint Role of chemotherapy in the treatment of gastroesophageal cancers
    Jimmy J Hwang
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Oncology (Williston Park) 21:579-86; discussion 587, 591-2. 2007
    ..Several new chemotherapy agents have demonstrated activity in these diseases, but the best chemotherapy remains to be determined. This paper will review the role of chemotherapy in gastroesophageal cancers...
  2. pmc A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors
    John Marshall
    Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA
    Invest New Drugs 31:399-408. 2013
    ..A Phase I study to determine the maximum tolerated dose (MTD) and pharmacokinetics of afatinib (BIBW 2992), a novel irreversible ErbB Family Blocker, administered orally once daily in a 3-week-on/1-week-off dosing schedule...
  3. ncbi request reprint Combined inhibition of topoisomerases: a phase I. Study of irinotecan and epirubicin
    Jimmy J Hwang
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, USA
    Oncology (Williston Park) 17:46-51. 2003
    ..Other toxicities were acceptable and non-dose-limiting. Accrual of patients continues, at level 3A (irinotecan at 75 mg/m2, epirubicin at 25 mg/m2)...
  4. ncbi request reprint Improving the toxicity of irinotecan/5-FU/leucovorin: a 21-day schedule
    Jimmy J Hwang
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, USA
    Oncology (Williston Park) 17:37-43. 2003
    ....
  5. ncbi request reprint Irinotecan and 5-FU/ leucovorin in metastatic colorectal cancer: balancing efficacy, toxicity, and logistics
    Jimmy J Hwang
    Lombardi Comprehensive Cancer Center Washington, DC 20007, USA
    Oncology (Williston Park) 18:26-34. 2004
    ..This article reviews the various combinations of irinotecan with 5-FU/leucovorin...
  6. ncbi request reprint Locally advanced esophageal carcinoma: at the crossroads of evidence-based medicine and patient care
    Jimmy J Hwang
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Clin Adv Hematol Oncol 1:289-91; discussion 292. 2003
  7. ncbi request reprint Capecitabine: fulfilling the promise of oral chemotherapy
    Jimmy J Hwang
    Georgetown University Medical Center, Lombardi Cancer Center, Washington DC 20007, USA
    Expert Opin Pharmacother 3:733-43. 2002
    ....
  8. pmc A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies
    Michael J Pishvaian
    Lombardi Comprehensive Cancer Center, Developmental Therapeutics Program, Georgetown University Medical Center, Washington, DC 20007, USA
    Cancer 118:5403-13. 2012
    ..The authors conducted a phase 1 study to determine the recommended phase 2 dose, safety, tolerability, and pharmacokinetics of efatutazone...
  9. pmc Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic cancer
    Xuefei Tian
    Division of Hematology and Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA
    Oncol Lett 11:1645-1650. 2016
    ..Additional investigation is required with regard to the application of the miRNA panel investigated in the present study as a potential predictor of patient responses to anti-EGFR/HER2 treatment...
  10. pmc Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma
    Jimmy J Hwang
    Lombardi Cancer Center, Georgetown Medical Center, 3800 Reservoir Road NW, Washington, DC 20007 2113, USA
    Clin Cancer Res 16:4038-45. 2010
    ..The two studies, GX001 and GX005, evaluated the safety and tolerability of weekly 1-hour and 3-hour infusions of obatoclax, respectively...
  11. ncbi request reprint Maintenance therapy with capecitabine in patients with resected pancreatic adenocarcinoma after adjuvant therapy
    Xuezhong Yang
    Georgetown University Hospital Lombardi Cancer Center, Washington, DC Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC Georgetown University Hospital, Washington, DC
    J Clin Oncol 30:333. 2012
    ..To evaluate this hypothesis, we retrospectively evaluated our patient (pts) who were treated with maintenance capecitabine (cape)...
  12. doi request reprint Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer
    Zheng Wu
    Division of Hematology and Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, 3800 Reservoir Road, NW, Washington, DC, 20007, USA
    Cancer Chemother Pharmacol 76:1309-14. 2015
    ..We conducted a single-arm phase II study to evaluate the combination of lapatinib and capecitabine in the second-line treatment of metastatic, gemcitabine-refractory pancreatic cancer...
  13. ncbi request reprint Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial
    Ramesh K Ramanathan
    University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15232, USA
    Cancer Invest 22:858-65. 2004
    ....